Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02438826 · ClinicalTrials.gov registry record · Phase 3
A Study of Galcanezumab in Participants With Chronic Cluster Headache
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
NCT02438826 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 240 participants.
The verdict
NCT02438826, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic cluster headache.
Interventions
- DRUG Placebo
- DRUG Galcanezumab 300 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2015-06-18 |
| Est. Completion | 2019-08-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02438826
The ClinicalTrials.gov registry entry for NCT02438826 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02438826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02438826 about?
NCT02438826 is a clinical study titled "A Study of Galcanezumab in Participants With Chronic Cluster Headache". The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic cluster headache.
What is the current status of trial NCT02438826?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2015-06-18. Estimated completion is 2019-08-14.
What interventions are being tested in trial NCT02438826?
The interventions under investigation include: Placebo (DRUG), Galcanezumab 300 mg (DRUG).
Who is sponsoring clinical trial NCT02438826?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.